Neonatal and fetal effects of antithyroid peroxidase positivity in hypothyroidism in pregnancy - A hospital-based prospective analytical study by Gupta, Tuhina et al.
Vol 6 | Issue 2 | February 2019 Indian J Child Health 79
Original Article
Neonatal and fetal effects of antithyroid peroxidase positivity in hypothyroidism 
in pregnancy - A hospital-based prospective analytical study
Tuhina Gupta1, Poonam Mani2, Abha Gupta3, Lalita Yadav4
From 1Junior Resident, 2Professor, 3Senior Resident, 4Assistant Professor, Department of Obstetrics and Gynaecology, Neta Ji Subhash Chandra Bose 
Subharti Medical College and Associated Chhatrapati Shivaji Subharti Hospital, Meerut, Uttar Pradesh, India
Correspondence to: Dr. Tuhina Gupta, 730, Udyan 1, Eldeco Colony, Lucknow, Uttar Pradesh, India. E-mail: tuhinaemail@gmail.com
Received - 18 January 2019 Initial Review - 10 February 2019 Accepted - 18 February 2019
The fetus is entirely dependent on transplacental maternal thyroid hormone supply until around 18 weeks of gestation [1]. Even subsequently, maternal thyroid 
hormone transfer to the fetus continues right up to delivery [2]. 
Thyroid disorders can, therefore, affect the fetal and neonatal 
outcomes from the beginning of pregnancy till after delivery. 
The most prevalent of these is subclinical hypothyroidism and 
autoimmune hypothyroidism. Thyroid antibody positivity has 
also been shown to be a risk factor for perinatal death [3]. The two 
important antibodies which are implicated are antithyroglobulin 
and antithyroid peroxidase (TPO) antibody, the latter being more 
significant. Mild thyroid dysfunction, characterized by increased 
thyroid-stimulating hormone (TSH) with normal FT4 levels, is 
frequently observed in the 1st month of life in neonates born from 
mothers affected by autoimmune thyroiditis. The majority of 
them undergo complete and spontaneous normalization of TSH 
value [4].
Psychomotor delay has been reported in the offspring of TPO 
antibody-positive mothers independently of thyroid dysfunction 
in apparently iodine-replete populations [5]. An increased 
incidence of neurodevelopmental deficits has also been reported in 
children whose mothers had subclinical hypothyroidism early in 
pregnancy [6]. Timely treatment of maternal hypothyroidism has 
shown to reduce the risk of neurodevelopmental deficits in the 
offspring. The stage of development, during which the lack of T4 
in the fetus is most detrimental for neurodevelopment, is thought 
to be the first trimester [7].
Congenital hypothyroidism is also an associated consequence 
of maternal uncontrolled hypothyroidism in pregnancy. The 
incidence ranges from 1:3000 to 1:4000 neonates, but a recent 
Indian study has found the incidence to be about 1:1130 
neonates [8]. Screening is done by measuring TSH in sample 
collected at 48–72 h after birth [9]. The second sampling is done 
at 2 weeks for premature, sick babies or babies <1.5 kg [10]. 
According to the American Academy of Pediatrics guidelines, 
neonates with serum TSH >40 mIU/L should be diagnosed 
with congenital hypothyroidism. In India, TSH cutoff values 
are >34 mIU/L during 24–48 h of life and >20 mIU/L after 48 h 
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on repeat filter paper TSH and >40 mIU/L at any age [10]. In 
general, a TSH ≥40 mIU/L on the 2–4 days of life warrants 
therapy, whereas values between 15 and 40 mIU/L may be 
carefully reassessed [11]. Therefore, we need to identify and 
correct hypothyroidism in pregnancy as well as screen all the 
newborns with serum TSH to recognize and treat congenital 
hypothyroidism at the earliest.
MATERIALS AND METHODS
It was a hospital-based prospective analytical study conducted 
over a period of 2 years from June 2016 to May 2018 in a tertiary 
care teaching institution of north India. All pregnant women 
reporting to the outpatient department in the first trimester, who 
did not have any of the conditions mentioned in the exclusions, 
were included in the study. Women with multiple pregnancies, 
chronic hypertension and chronic renal disease, pregnancy 
complicated by previous history of diabetes type 1 and type 2, 
TORCH infection, Rh-negative women, pregnant women whose 
first visit was in labor with no previous investigations of thyroid 
status, and known hyperthyroid pregnant women were excluded 
from the study.
Pregnant women, who fulfilled the criteria, were recruited 
in the study after taking written consent. A detailed history 
was taken and thorough examination was done. Serum TSH 
level of >2.5 µIU/L in the first trimester was considered as 
hypothyroidism and these patients were categorized as “Cases” 
and further investigated with free T4 and anti-TPO antibody. 
Women with TSH level <2.5 µIU/L were considered normal 
(euthyroid) and were categorized as “Controls.” Cases and 
controls were taken in the ratio of 1:1. The anti-TPO test was done 
by IMTEC - TPO ELISA test kit - Human Diagnosis, Germany, 
and read on ROBONIK ELISA analyzer. Interpretation was as 
follows: Negative (<14.5 IU/ml), equivocal (14.5–35.5 IU/ml), or 
positive (>35.5 IU/ml).
All hypothyroid women were followed up for maternal and 
baby well-being. Baby weight at birth and 1- and 5-min Apgar 
was taken. The babies, born to these women, were tested on day 
3 of life, for hypothyroidism, by serum TSH levels. This was 
repeated at 1 month of age, if indicated. Serum bilirubin was 
done, if clinically jaundice was noted. The data were analyzed 
using Chi-square test and p values were calculated. Relative risk 
with 95% confidence interval (CI) was also calculated. p≤0.05 
was considered as statistically significant.
RESULTS
A total of 309 women were included in the study; of which, 159 
hypothyroid women were categorized as “Cases” and 150 euthyroid 
women were taken as “Controls.” Three groups were demographically 
comparable as seen in Table 1. Of 309 cases, 19 women had positive 
anti-TPO test and remaining had negative results. Demographic 
profile of the cases and controls is presented in Table 1.
The incidences of fetal and neonatal complications in the 
various groups are given in Table 2. These were analyzed in 278 
women after subtracting the number of women who had IUD 
(22 women) and those who aborted (9 women), including 142 
women in control and 136 women in the hypothyroid group. Of 
the hypothyroid women, n=15 in the anti-TPO-positive groups 
and n=121 in the anti-TPO-negative group.
According to our results, the incidence of meconium-
stained liquor and intrauterine growth retardation (IUGR) was 
not significantly different between cases and controls and also 
between anti-TPO positive and negative women. The number of 
babies requiring neonatal intensive care unit (NICU) admission for 
various reasons was more in the hypothyroid group as compared 
to that in the control group (RR 1.8; CI 1.18–2.7, p=0.004). The 
incidence of low or very low birth weight was more in cases than 
in the control group (50% vs. 26.05%), which was statistically 
significant (p=0.0003, RR 1.92; CI 1.39–2.65). However, this 
difference not statistically significant between anti-TPO positive 
and negative women (RR 1.39 CI 0.93–2.08). Similarly, neonatal 
deaths were significantly more in cases than in the control group 
(p=0.007, RR 4.88 CI 1.42–16.74); however, there was no 
difference between anti-TPO positive and negative groups.
In our study, 16 (5.18%) neonates had different congenital 
anomalies with an incidence of 7.54% in cases as compared to 
2.66% in the control group (RR 2.83; CI 0.93–8.5). However, 
it was not significant between anti-TPO positive and negative 
groups (Table 3). The incidence of intrauterine death (IUD) 
was also more in cases than in controls (p=0.038, RR 2.51; CI 
1.01–6.25).
Out of the babies of 159 hypothyroid mothers, serum TSH 
levels on the day of life 3 could be done for 137, and out of them, 
6 (4.37%) babies were hypothyroid requiring further evaluation 
(p=0.045, RR 3.68; CI 0.72–18.77) as shown in Table 4.
DISCUSSION
Hypothyroidism in pregnancy has been shown to be associated 
with NICU admission and lower intelligence scores [12,5]. 








Age (years) 150 19 140
18–20 2 1 5
21–30 134 11 114
31–40 14 7 21
Mean age (years) 25.87±3.56 29.26±4.71 26.34±4.35
Parity
Primigravida 55 4 35
Multigravida 92 14 103
Grand multipara 3 1 2
Mode of delivery
Abortion 2 0 9
LSCS 47 4 102
Vaginal 101 15 198
TPO: Thyroid peroxidase
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In our study, the incidence of NICU admissions was more in 
the hypothyroid group as compared to the euthyroid group 
(33.09% vs. 18.3%; p=0.004), but anti-TPO positivity was not an 
independent risk factor for the same.
In our study, the incidence of low birth weight (LBW) was 
found to be significantly more in the hypothyroid mothers (50% vs. 
26.05%; p=0.0003). Anti-TPO-positive mothers did have more 
LBW infants as compared to anti-TPO-negative mothers (66.67% 
vs. 47.93%), but it was not statistically significant. Hence, 
hypothyroidism predisposes the babies to LBW, but the risk is 
not increased with anti-TPO positivity. In a study was done by 
Shameel et al. [13], the incidence of LBW babies was more in the 
uncontrolled hypothyroid group (p<0.005). Nazarpour et al. [14] 
have also reported a higher incidence of LBW in mothers with 
clinical hypothyroidism. Chen et al. [15]reported a significant 
association between subclinical hypothyroidism and the risk of 
having an LBW baby (p<0.001).
In our study, another significant association was with neonatal 
death (9.55% in hypothyroid mothers vs. 2.11% in the controls, 
p=0.007). Anti-TPO positivity did not have any added risk for 
neonatal death. We also found that the risk of IUD was more 
in the hypothyroid mothers as compared to euthyroid mothers 
(10.06% vs. 4%; p=0.038). Anti-TPO-positive mothers had an 
even greater risk of IUD. Hence, both hypothyroidism and anti-
TPO positivity raise the risk of IUD. We found that 5.18% of 
women had babies with various congenital anomalies such as 
renal agenesis, congenital talipes equinovarus, anencephaly, and 
gastroschisis. The incidence was more in the hypothyroid women 
(7.54% vs. 2.66%; p=0.026); however, anti-TPO positivity did 
not have an increased risk. The risk of stillbirth and congenital 
malformation was not found to be increased in women with 
subclinical hypothyroidism in a study by Chen et al. [15].
In our study, hypothyroidism in the babies was also looked 
for and screening was done by checking day 3 TSH in all the 
babies of hypothyroid mothers. A total of 4.37% of the babies had 
a raised TSH which needed further evaluation. Anti-TPO-positive 
mothers had 12.5% of babies with raised TSH as compared to 
3.30% in the anti-TPO-negative group (p=0.045). Hence, anti-
TPO positivity was a risk factor for hypothyroidism in the 
newborn which could be congenital hypothyroidism. Hence, we 
suggest that all women with hypothyroidism should have their 
babies screened with TSH levels, and even more so if the mother 
is anti-TPO positive. Rovelli et al. [4] conducted a study on 129 
neonates of mothers with autoimmune thyroiditis and found 
that transient mild elevation of serum TSH above the normal 
reference value for age is frequently observed in the 1st month 
of life in these infants. Persistent hyperthyrotropinemia requiring 
replacement therapy was observed in 2.2% of these neonates.
Hypothyroidism is significantly associated with an increased 
risk of IUD, NICU admissions, neonatal jaundice, LBW, 
Table 2: Various fetal complications in different groups











Number 142 15 121 136 278 - -
Meconium 16 (11.26) 1 (6.67) 15 (12.39) 16 (11.76) 32 (11.51) 0.896 0.515
NICU admission 26 (18.3) 4 (26.67) 41 (33.89) 45 (33.09) 71 (25.54) 0.004 0.575
Jaundice 18 (12.6) 2 (13.34) 27 (22.31) 29 (21.32) 47 (16.9) 0.027 0.423
IUGR 6 (4.22) 2 (13.34) 9 (7.43) 11 (8.09) 17 (6.11) 0.180 0.429
LBW/VLBW 37 (26.05) 10 (66.67) 58 (47.93) 68 (50) 105 (37.76) 0.0003 0.170
Neonatal death 3 (2.11) 1 (6.67) 12 (9.91) 13 (9.55) 16 (5.75) 0.007 0.689
TPO: Thyroid peroxidase, IUGR: Intrauterine growth retardation, NICU: Neonatal intensive care unit, LBW/VLBW: Low birth weight/very low birth weight
Table 3: Various fetal complications in different groups











Number 150 19 140 159 309 - -
Congenital anomaly 4 (2.66) 2 (10.52) 10 (7.14) 12 (7.54) 16 (5.18) 0.026 0.603
IUD 6 (4.00) 4 (21.05) 12 (9.02) 16 (10.06) 22 (7.12) 0.038 0.044
TPO: Thyroid peroxidase, IUD: Intrauterine death
Table 4: Distribution of hypothyroid babies in various groups
Anti-TPO positive Anti-TPO negative Total hypothyroid mothers p value
Number of mothers 19 140 159
TSH done on day 3 (%) 16 (84.21) 121 (86.43) 137 0.729
Hypothyroid babies (%) 2 (12.5) 4 (3.30) 6 (4.37) 0.045
TSH: Thyroid-stimulating hormone, TPO: Thyroid peroxidase
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congenital anomalies, and neonatal deaths. Hypothyroidism may 
be associated with an increased risk of IUGR, although it was non-
significant. Anti-TPO positivity may be associated with IUGR, 
LBW, and congenital anomaly, but they were not statistically 
significant in our study. We recommend all hypothyroid women 
should be tested for the presence of anti-TPO antibodies.
Strength of the study was that antenatal data were also 
available and babies were followed up from fetal till neonatal 
period. Hence, we knew about the effects of hypothyroidism 
right from conception till delivery and even later. Limitation of 
our study was a small sample size and no anti-TPO testing done 
for the babies. However, studies with a larger sample size are 
needed to confirm our findings and provide further evidence of 
the importance of anti-TPO positivity in pregnancy and its effects 
on the newborns.
CONCLUSIONS
We found that anti-TPO positivity is significantly associated 
with increased risk IUD and hypothyroidism in the newborn of 
the hypothyroid mother. Hence, screening with serum TSH is 
recommended in all babies of hypothyroid women.
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